Log in to search using one of your social media accounts:

 

Headache Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial (S52.008)
Conclusions:Our findings provide class I evidence that CSF pressure and headaches are independent features of IIH.Study Supported by: National Eye Institute (1U10EY017281-01A1, DCBC 1U10EY017387-01A1, ARRA for NORDIC 3U10EY017281-01A1S1, and DCBC 1U10EY017387-01A1S1, and supplements for NORDIC 3U10EY017281-01A1S2)Disclosure: Dr. Friedman has received personal compensation for activities with Allergan, Teva, Eli Lilly, Avenir, Zosano, Amgen, Alder, Supernus and Trigemina as a speaker or advisory board member. Dr. Mejico has nothing to disclose. Dr. Subramanian has nothing to disclose. Dr. Quiros has nothing to disclose. Dr....
Source: Neurology - April 17, 2017 Category: Neurology Authors: Friedman, D., Mejico, L., Subramanian, P., Quiros, P., McDermott, M. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

The Effect of Psychiatric Symptoms on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study (S52.007)
Objective:To examine the separate and joint influences of depression and anxiety symptoms on headache-related disability in people with migraine (episodic and chronic).Background:Many studies have reported that psychiatric comorbidities, particularly depression and anxiety, have higher prevalence in people with migraine. However, the relative contributions of these psychiatric comorbidities to headache-related disability are unknown.Design/Methods:This cross-sectional analysis of data from CaMEO, a web-panel study, assessed sociodemographic and headache features, headache-related disability (Migraine Disability Assessment ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Lipton, R., Chu, M. K., Seng, E., Reed, M., Fanning, K., Adams, A. M., Buse, D. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

Statin and Vitamin D for Prevention of Migraine (S52.006)
Objective:Our aim was to assess the efficacy and tolerability of simvastatin plus vitamin D3 for migraine prevention in adults with episodic migraine.Background:Both statins and higher vitamin D levels have been shown to have anti-inflammatory and immunomodulatory effects. We previously identified a beneficial interaction between statins and higher vitamin D levels on the outcome of pain. We hypothesized that combining a statin with a vitamin D3 supplement would decrease migraine attacks.Design/Methods:We performed a randomized, double-blind, placebo-controlled trial with a 12-week baseline period and 24-week intervention ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Buettner, C., Nir, R.-R., Burstein, R. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

Efficacy of Zolmitriptan Nasal Spray for the Treatment of Acute Migraine in Adolescents: Subgroup analysis by Age (S52.005)
Objective:Analyze the effect of patient age on the effectiveness of zolmitriptan nasal spray (ZNS) in adolescent migraine, using patient subgroups of younger (12–14 years) and older (15–17 years) adolescents.Background:Acute migraine is common in adolescents, but proven-effective therapies available to adolescent migraineurs are limited. ZNS was shown to be effective and well tolerated in the treatment of acute migraine in adolescents.Design/Methods:Adolescents with an established diagnosis of migraine with or without aura were enrolled in a randomized, double-blind, parallel-group study (NCT01211145). Non-resp...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Winner, P., Rubens, R., Rustay, N., Khanna, S., Wray, H. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

A Multicenter, Prospective, Single Arm, Open Label, Post-Market, Observational Study to evaluate the use of sTMS in reduction of Migraine Headache (ESPOUSE Study) (S52.004)
Objective:To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the treatment of migraine.Background:sTMS is an FDA-approved acute treatment for migraine with aura. Open label patient experience in the United Kingdom has suggested a possible preventive benefit in migraine.Design/Methods:The ESPOUSE Study was a multicenter, prospective, single-arm, open label, observational study to evaluate sTMS for the treatment of migraine. From December 2014 to March 2016, 263 patients with migraine were consented to complete a 1-month baseline headache diary followed by 3 months of treat...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Starling, A. J., Tepper, S., Marmura, M. J., Shamim, E. A., Robbins, M., Hindiyeh, N., Charles, A. C., Goadsby, P. J., Lipton, R. B., Silberstein, S. D., Dodick, D. W. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine. (S52.003)
Objective:To evaluate the efficacy and safety of ALD403, an anti-CGRP antibody, for the prevention of chronic migraine.Background:Calcitonin gene-related peptide (CGRP) is involved in the pathophysiology of migraine. Antagonists of CGRP may have a pivotal role in preventing chronic migraine.Design/Methods:Patients with 15 to 28 headache days per month, of which at least 8 were migraine days were randomized to receive a single intravenous dose of ALD403 300mg, 100mg, 30mg, 10mg or placebo. The primary endpoint was the percentage of patients achieving a 75% reduction in migraine days per month from baseline to week 12. Stati...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Dodick, D., Goadsby, P., Silberstein, S., Lipton, R., Hirman, J., Smith, J. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study (S52.002)
This study investigates erenumab, a fully human monoclonal antibody that inhibits the CGRP receptor, in patients with CM.Design/Methods:In this phase 2, randomized, double-blind, placebo-controlled study, 667 adults with CM (≥15 headache days/month; ≥8 migraine days/month) were randomized (3:2:2) to monthly subcutaneous placebo or erenumab 70 mg or 140 mg. The primary endpoint (change from baseline in monthly migraine days [MMD]) and secondary endpoints (≥50% reduction in MMD and change from baseline in acute migraine-specific medication days and cumulative headache hours) were evaluated at the end of the double-b...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Tepper, S., Widnell, K., Dolezil, D., Ashina, M., Reuter, U., Brandes, J. L., Silberstein, S., Winner, P., Leonardi, D., Mikol, D. Tags: Headache: Clinical Trials and Disease Burden Source Type: research

Incidence of Stroke in the US Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) Cohort (S51.008)
Objective:Conduct rigorous epidemiologic studies to define the incidence of stroke in the largest study of adjudicated strokes in a HIV population.Background:Stroke is increasingly common in HIV, likely due to aging of the population, cumulative exposure to HIV and possibly medication side effects. Additional studies are needed to better understand, prevent and treat these strokes.Design/Methods:We developed a rigorous adjudication protocol to identify stroke types and subtypes in the CNICS cohort. Two neurologists reviewed each case, and a third if discrepancies occurred. Incidence was age standardized (AS) to the 2010 US...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Tirschwell, D., Chow, F., Becker, K., Marra, C., Zunt, J., Ho, E., Kalani, R., Huffer, A., Nance, R., Williams-Nguyen, J., Burkholder, G., Moore, R., Mathews, W., Eron, J., Drozd, D., Kitahata, M., Saag, M., Crane, H. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Recurrent Stroke after Silent Brain Infarction in Patients with Primary Brain Tumors (S51.007)
Conclusions:The short-term risk of recurrent ischemic stroke in patients with PBTs was substantial and the risk was comparable whether the stroke was silent or symptomatic.Study Supported by: Babak Navi was supported by grants from the NINDS (K23NS091395) and the Florence Gould Endowment for Discovery in Stroke. Hooman Kamel was supported by grants from the NINDS (K23NS082367) and the Michael Goldberg Stroke Research Fund.Disclosure: Dr. Parikh has nothing to disclose. Dr. Burch has nothing to disclose. Dr. Kamel has received personal compensation for activities with Genentech as a speaker. Dr. Kamel has received personal ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Parikh, N., Burch, J., Kamel, H., DeAngelis, L., Navi, B. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Associations between Parkinson Disease and Stroke (S51.006)
Conclusions:Among Medicare beneficiaries, the relationships between stroke and PD were similar to those between stroke and AD. As in AD, a link may exist between cerebrovascular disease and PD.Study Supported by: Hooman Kamel was supported by grants from the NINDS (K23NS082367) and the Michael Goldberg Stroke Research Fund. Babak Navi was supported by grants from the NINDS (K23NS091395) and the Florence Gould Endowment for Discovery in Stroke.Disclosure: Dr. Kummer has nothing to disclose. Dr. Aaroe has nothing to disclose. Dr. Kamel has received personal compensation for activities with Genentech as a speaker. Dr. Kamel h...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kummer, B., Aaroe, A., Kamel, H., Iadecola, C., Navi, B. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Leukocyte response in ischemic stroke is regulated by let7i microRNA (S51.005)
Objective:Evaluate microRNA let7i in ischemic stroke and its regulation of leukocytes.Background:The immune system responds rapidly following ischemic brain injury and can contribute to the final extent of brain damage. microRNA are differentially expressed in leukocytes following ischemic stroke and may regulate the immune response to ischemic brain injury. In our initial study we identified microRNA let7i to be among the most significantly decreased microRNA in leukocytes of patients with ischemic stroke.Design/Methods:A total of 212 patients were studied; 106 with acute ischemic stroke and 106 risk factor matched contro...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Jickling, G., Ander, B., Shroff, N., Stamova, B., Liu, D., Sharp, F. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Histopathological differences between the anterior and posterior cerebral circulation as a function of aging (S51.004)
Conclusions:Posterior circulation arteries differ pathologically from the anterior circulation in the degree of wall thickening, elastin loss and concentric intimal thickening. Understanding the drivers of posterior circulation remodeling may broaden the understanding of brain arterial remodeling and open new perspectives to modify it.Disclosure: Dr. Roth has nothing to disclose. Dr. Morgello has nothing to disclose. Dr. Goldman has nothing to disclose. Dr. Mohr has nothing to disclose. Dr. Elkind has received personal compensation in an editorial capacity for Neurology. Dr. Marshall has received personal compensation in a...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Roth, W., Morgello, S., Goldman, J., Mohr, J., Elkind, M., Marshall, R., Gutierrez, J. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Long-term Risk of Complications after Percutaneous Transcatheter Closure of Patent Foramen Ovale (S51.003)
Conclusions:Approximately 1 in 6 patients who undergo percutaneous transcatheter closure of PFO after stroke or transient ischemic attack experience a serious complication or death within 5 years.Study Supported by:Dr. Gialdini is supported by the Feil Family Foundation.Dr. Navi is supported by NIH grant K23NS091395 and the Florence Gould Endowment for Discovery in Stroke.Dr. Iadecola is supported by NIH grants R37NS089323-02, R01NS034179-21, R01NS037853-19, and R01 NS073666-04.Dr. Kamel is supported by NIH grants K23NS082367 and R01NS097443 as well as the Michael Goldberg Research Fund.Disclosure: Dr. Merkler has nothing ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Merkler, A., Gialdini, G., Yaghi, S., Okin, P., Iadecola, C., Navi, B., Kamel, H. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

"Worth the Walk:" A Randomized Controlled Trial of a Walking Intervention to Decrease Stroke Risk Among Minority Seniors (S51.002)
Conclusions:We successfully implemented a community-partnered, culturally-tailored, sustainable program to increase walking in minority seniors. Preliminary data analysis suggests improvement in non-sustained increases in steps/day. Next steps include more extensive data analyses, including stakeholder interviews, and examination of participant-level and organizational features associated with more successful study outcomes and program implementation.Study Supported by: - University of California, Los Angeles (UCLA) and Charles Drew University (CDU), Resource Centers for Minority Aging Research Center for Health Improvemen...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Song, S., Araiza, D., Reyes, C., Willis, P., Choi, S., Kotick, J., Jimenez, E., Ma, S., Trejo, L., Carrillo, C., Sarkisian, C. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients (S51.001)
Conclusions:Among NVAF patients with a prior history of SSE, rivaroxaban reduced ischemic stroke and ICH risk versus warfarin and did not significantly impact major bleeding. Apixaban did not significantly alter patients’ risk of SSE or major bleeding compared to warfarin in this high-risk population.Study Supported by: Bayer Pharma AGDisclosure: Dr. Coleman has received personal compensation for activities with Janssen Scientific affairs, LLC, Bayer Pharma AG, and BIPI . Dr. Coleman has received research support from Janssen Scientific Affairs, LLC, and Bayer Pharma AG. Dr. Bunz has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Coleman, C., Bunz, T. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Investigating the role of fibrinogen and iron in inflammatory demyelination using combined high-resolution mri and histopathology in marmoset experimental autoimmune encephalomyelitis (s50.008)
Conclusions:In conclusion, our results show that fibrinogen is a reliable marker of the early, active stage of EAE lesion development, whereas iron is a late marker and as such is unlikely to result directly from oligodendrocyte lysis.Disclosure: Dr. Lee has nothing to disclose. Dr. Ha has nothing to disclose. Dr. Luciano has nothing to disclose. Dr. Leibovitch has nothing to disclose. Dr. Lefeuvre has nothing to disclose. Dr. Sati has nothing to disclose. Dr. Schindler has nothing to disclose. Dr. Akassoglou has nothing to disclose. Dr. Silva has nothing to disclose. Dr. Jacobson has nothing to disclose. Dr. Reich has rec...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Lee, N., Ha, S.-K., Luciano, N., Leibovitch, E., Lefeuvre, J., Sati, P., Schindler, M., Akassoglou, K., Silva, A., Jacobson, S., Reich, D. Tags: MS Novel Therapeutics and Animal Models Source Type: research

Fc RI (CD64) Receptors Are Widely Expressed on CNS Neurons and Are Required for Neuronal IgG Binding and Uptake: Implications for Antibody-Mediated Neuronal Injury (S50.007)
Conclusions:FcRI receptors are expressed on neurons throughout the brains of mice and rats and appear essential for IgG antibody incorporation into neurons. Although the biological function of neuronal Fc receptors is unknown, their presence suggests a mechanism through which antibodies reactive with intracellular neuronal proteins could gain access to their target antigens to cause neuronal injury and neurological disease.Study Supported by: This study was supported by a Merit Review award from the United States Department of Veterans Affairs and a grant from the Western Institute for Biomedical ResearchDisclosure: Dr. Li...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Liu, S., Hill, K., Wood, B., Clawson, S., Clardy, S., Carlson, N., Greenlee, J. Tags: MS Novel Therapeutics and Animal Models Source Type: research

The characterisation of an inducible demyelination zebrafish model to aid the investigation and development of novel therapeutics in multiple sclerosis (S50.006)
Conclusions:Here we describe a novel zebrafish model of demyelination that has highlighted the key differences in oligodendrocyte development and differentiation during the processes of demyelination and remyelination. This model is now being used for identifying molecular targets that enhance re-myelination and testing various therapeutic agents that accelerate remyelination.Disclosure: Dr. McGown has nothing to disclose. Dr. Sharrack has nothing to disclose. Dr. Ramesh has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: McGown, A., Sharrack, B., Ramesh, T. Tags: MS Novel Therapeutics and Animal Models Source Type: research

Serum and CSF Neurofilament Light Levels Predict Long-Term Outcomes in Multiple Sclerosis Patients (S50.005)
Objective:To evaluate serum and CSF neurofilament light (NfL) as a prognostic biomarker for long-term disease outcome in multiple sclerosis (MS) patients.Background:An objective, quantitative and reliable prognostic biomarker could improve outcomes through more appropriate treatment selection. NfL is a proposed marker of neuronal injury, with increased CSF and serum levels reported in several neurodegenerative disorders, including MS. The value of NfL, specifically serum NfL, in predicting long-term outcome in MS is largely unknown.Design/Methods:CSF NfL was measured in 234 MS patients from the 2-year randomized, placebo-c...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kuhle, J., Plavina, T., Barro, C., Sangurdekar, D., Singh, C., DeMoor, C., Engle, B., Fisher, E., Kappos, L., Rudick, R., Goyal, J. Tags: MS Novel Therapeutics and Animal Models Source Type: research

Accelerated cellular senescence in a model of multiple sclerosis (S50.004)
Objective:To test the hypothesis that chronic demyelination is associated with accelerated cellular senescence.Background:Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease affecting the CNS. Evidence suggests that age-related neurodegenerative processes drive disability progression in the progressive phases of MS, but the exact mechanisms are poorly understood. Cell senescence (CS) is an age-dependent process, known to be accelerated by chronic inflammation. Except for its beneficial role in preventing damaged cells from becoming oncogenic, it is thought that accelerated CS contributes to loss of ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Papadopoulos, D., Karamita, M., Mitsikostas, D. D., Gorgoulis, V., Probert, L., Nicholas, R. Tags: MS Novel Therapeutics and Animal Models Source Type: research

A high-throughput screen identifies a candidate molecule that promotes remyelination with significant translational potential (S50.003)
Conclusions:Taken together, BZA represents a particularly potent and attractive SERM that could be mediating OPC differentiation and myelination effects, with significant translational potential.Study Supported by: National Multiple Sclerosis Society.Disclosure: Dr. Rankin has nothing to disclose. Dr. Shen has nothing to disclose. Dr. Mei has nothing to disclose. Dr. Desponts has received personal compensation for activities with Inception Sciences as an employee. Dr. Desponts holds stock and/or stock options in Inception Sciences. Dr. Lorrain has received personal compensation for activities with Inception. Dr. Green has ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Rankin, K., Shen, Y.-A., Mei, F., Desponts, C., Lorrain, D., Green, A., Chan, J., Bove, R. Tags: MS Novel Therapeutics and Animal Models Source Type: research

CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study (S50.002)
Conclusions:Treatment with CHS-131 was generally well-tolerated, and the 3mg dose resulted in a significant decrease in the incidence of new CE lesions as compared with placebo over 6 months.Study Supported by:This study was supported by a grant from the Ministry of Industry and Trade of the Russian Federation and sponsored by Coherus BioSciences and Zao InteKrin.Disclosure: Dr. Weinstein has received personal compensation for activities with InteKrin Therapeutics, Inc. and Coherus BioSciences as a consultant. Dr. Weinstein has received compensation for serving on the Board of Directors and the Scientific Advisory Board of...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Weinstein, D., Boyko, A., Pugliese, L., Tang, H., Lanfear, D., Zivadinov, R., Finck, B. Tags: MS Novel Therapeutics and Animal Models Source Type: research

Astrocytic Junctional Adhesion Molecule-A (JAM-A) Promotes CNS Inflammatory Lesion Pathogenesis (S50.001)
Conclusions:Reactive astrocytes upregulate the cell adhesion molecule, JAM-A in inflammatory lesions, which promotes leukocyte migration and tissue damage during CNS inflammation and clinical disability in a model of MS.Study Supported by:S.H. is the recipient of grant funding from NIH R25NS079102 and a post-doctoral Neuroscience fellowship from the Leon Levy Foundation. This work was additionally supported by NINDS Research Grants, R01NS062703 and R01NS085103 (G.R.J.), and by NIH R24CA095823 (to the MSSM Microscopy Facility). Additional support was provided by National MS Society research grants RG5024 and RG-1501-02870 (...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chapouly, C., Gordon, A., Therattil, A., John, G., Horng, S. Tags: MS Novel Therapeutics and Animal Models Source Type: research

Sleep apnea during NREM but not REM inversely correlates with CSF amyloid beta 42 but not Tau levels (S49.004)
Conclusions:Non-REM SA is inversely associated with CSF Aβ42, suggesting that SA may be a modifiable risk factor for Alzheimer’s Disease.Study Supported by: Owens FoundationDisclosure: Dr. Werner has nothing to disclose. Dr. Abeson has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Solomon has nothing to disclose. Dr. Petrusky has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Spira has received personal compensation for activiteis with Pulmonary Disease and Critical Care Associates. Dr. Moghekar has received research support from GE Healthcare. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Werner, J. K., Abeson, K., Rao, A., Solomon, D., Petrusky, O., Wu, M., Spira, A., Moghekar, A. Tags: Best Of: Aging and Dementia Source Type: research

Blood Pressure Trajectories from Mid to Late Life and Risk of Dementia: The Framingham Study (S49.003)
Objective:To determine the association between blood pressure trajectories from mid-life (40–64y) to late-life (≥65y) and risk of dementia.Background:Hypertension is the most important modifiable risk factor for cerebrovascular pathology contributing to stroke and dementia. Yet the association between blood pressure and dementia is not well understood.Design/Methods:1440 (758 women) dementia-free Framingham Offspring participants who had previously attended 5 consecutive quadrennial examinations starting at mid-life (1983–1987, mean age 55y) until late-life (1998–2001, mean age 69y), and have been rigo...
Source: Neurology - April 17, 2017 Category: Neurology Authors: McGrath, E., Beiser, A., DeCarli, C., Plourde, K., Ramachandran, V., Greenberg, S., Seshadri, S. Tags: Best Of: Aging and Dementia Source Type: research

The Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) North American Rare Disease Clinical Research Consortium: Progress and Characterization of Initial Participants (S49.002)
Conclusions:ARTFL is actively enrolling participants across North America to characterize sporadic and familial FTLD. Clinical, biomarker, genetic and imaging data from ARTFL and LEFFTDS will soon be available to investigators worldwide.Study Supported by: NINDS and NCATS U54NS092089 through the Rare Disease Clinical Research NetworkDisclosure: Dr. Boxer has received personal compensation for activities with Abbvie, Asceneuron, Janssen, Merck for consulting. Dr. Rosen has nothing to disclose. Dr. Boeve has received research support from GE Healthcare, FORUM Pharmaceuticals, C2N Diagnostics and Axovant. Dr. Heuer has nothin...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Boxer, A., Rosen, H., Boeve, B., Heuer, H., Coppola, G., Dickerson, B., Bordelon, Y., Conwit, R., Dheel, C., Faber, K., Feldman, H., Fields, J., Fong, J., Foroud, T., Ghoshal, N., Graff-Radford, N., Grossman, M., Hsiung, G.-Y., Huey, E., Irwin, D., Kantar Tags: Best Of: Aging and Dementia Source Type: research

Ante mortem CSF tau levels correlate with post mortem tau pathology in FTLD (S49.001)
Objective:To test the hypotheses that 1) ante-mortem cerebrospinal fluid (CSF) levels of tau correlate with post-mortem tau pathology in frontotemporal lobar degeneration (FTLD) and 2) FTLD-Tau patients have higher phosphorylated-tau (p-tau) levels compared to FTLD-TDP while accounting for Alzheimer’s disease (AD) co-pathology.Background:CSF p-tau may discriminate the two major classes of FTLD pathology (i.e. tauopathy in FTLD-Tau, TDP-43 proteinopathy in FTLD-TDP) associated with a clinical diagnosis of frontotemporal dementia (FTD). However, coincident AD neuropathology may confound CSF levels of p-tau, and studies...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Irwin, D., Lleo, A., McMillan, C., Wolk, D., Van Deerlin, V., Shaw, L., Trojanowski, J., Grossman, M. Tags: Best Of: Aging and Dementia Source Type: research

Validation of i1 Biometrics Vector MouthGuard: Measuring Head Impact Frequency in Sport (S48.008)
Conclusions:We are currently in the process reassessing how we will analyze impact events in the video and would like to refrain from discussing preliminary results until we can insure consistency in our video analysis. At the time of the conference however we will present the sensitivity, specificity, and accuracy of the Vector MouthGuard.Disclosure: Dr. McKendry has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Blouin has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: McKendry, G., Brown, H., Blouin, J.-S. Tags: Practice, Policy, and Ethics Source Type: research

Factors in Unplanned Readmission or ED Visit within 30 Days of Discharge from an Inpatient Neurology Service (S48.007)
Objective:To identify factors associated with unplanned readmission or emergency department (ED) visit within 30 days after discharge from inpatient Neurology service.Background:Hospital readmission and ED visits shortly after evaluation during an inpatient stay are costly to the healthcare system. Few studies of this systemic problem have focused on inpatient neurology admissions.Design/Methods:We retrospectively reviewed 594 neurology inpatient discharges between July 2014 and June 2015 for adverse outcomes comprising an ED visit or readmission within 30 days of discharge. Stepwise selection for logistic regression was u...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ahmed, F., Balasetti, V., Sajja, K., Jaygaopal, L. A., Stenzel, L., Devarapalli, S., Pandit, A. A., Reddy, S. K., Smith, E., Ali, F.-a., Galla, K. M., Baang, H. Y., Maher, H., Samson, K., Kedar, S., Rizzo, M., Diesing, T. S., Castellon, M. G. Tags: Practice, Policy, and Ethics Source Type: research

Enhancing efficiency of the epilepsy center king faisal specialist hospital and research center - jeddah (kfsh&rc - jeddah) (s48.006)
Conclusions:LEAN PDCA methods can be applied to health care settings in Saudi Arabia. Our sensitivity analysis for the next 10 years projects a $14.000.000 savings compared to medical management without adding resources. After epilepsy surgery patients are reintegrated into society and participate in life.Disclosure: Dr. Al Said has nothing to disclose. Dr. Cupler has received personal compensation for activities with Sanofi as a member of their speaker bureau. Dr. Baeesa has nothing to disclose. Dr. Zabani has nothing to disclose. Dr. Lighter has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Al Said, Y., Cupler, E., Baeesa, S., Zabani, I., Lighter, D. Tags: Practice, Policy, and Ethics Source Type: research

A multimodal quality improvement program for delirium in stroke (S48.005)
Conclusions:Delirium prevention and management is critical to quality patient care and has not yet been effectively implemented among neurologic patients. We will discuss our ongoing efforts for delirium prevention in stroke patients.Disclosure: Dr. Ryan has nothing to disclose. Dr. Gormley has nothing to disclose. Dr. Jacobs has nothing to disclose. Dr. Cohen has received personal compensation for activities with EM Gladiators LLC. as a Medical app developer and Decibel Therapeutics as a consultant. Dr. Kimchi has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ryan, S., Gormley, V., Jacobs, C., Cohen, A., Kimchi, E. Tags: Practice, Policy, and Ethics Source Type: research

Reducing delays to imaging and thombolysis in acute stroke care (S48.004)
Objective:To reduce door to CT times to
Source: Neurology - April 17, 2017 Category: Neurology Authors: Caller, T., Rieser, C., Savelle, J., Norviel, J., Kisicki, J. Tags: Practice, Policy, and Ethics Source Type: research

Factors affecting post-discharge outcomes in hospital patients with non-surgical neurological diseases (S48.003)
Objective:To study patient, disease and process factors that affect post-hospitalization outcomes in patients with non-surgical neurological diseases.Background:Preventable readmissions are associated with increased healthcare costs. Unplanned neurology readmission rate was estimated to be 11% nationwide. Better discharge planning is needed to improve outcomes and mitigate costs.Design/Methods:We retrospectively reviewed all discharges from neurological sciences (except elective epilepsy monitoring unit) from July 2014– June 2015. Negative discharge outcomes included: death, emergency room visit, readmission within 3...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Galla, K. M., Alkhalifah, M., Pedavally, S., Mudugal, D., Balasetti, V., Sajja, K., Jayagopal, L. A., Ahmed, F., Devarapalli, S., Stenzel, L., Pandit, A. A., Reddy, S. K., Smith, E., Baang, H. Y., Ali, F.-a., Maher, H., Samson, K., Rizzo, M., Diesing, T. Tags: Practice, Policy, and Ethics Source Type: research

MyChart Enrollment and other Factors that Affect No Show Rates in the Neurology Resident Clinic (S48.002)
Conclusions:Our study indicates that the status of MyChart enrollment, age, race and physician referral have a significant impact upon no-show rates.Disclosure: Dr. Shah has nothing to disclose. Dr. Alshammaa has nothing to disclose. Dr. Affan has nothing to disclose. Dr. Schultz has nothing to disclose. Dr. Zaman has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Shah, K., Alshammaa, A., Affan, M., Schultz, L., Zaman, I. Tags: Practice, Policy, and Ethics Source Type: research

Implementation of an on-line communication interface ("Ask-a-doc") in a neurology department (S48.001)
Conclusions:AAD provides an interface between PCP and neurology specialist and can assist with determining if a patient needs to be seen urgently in the clinic, the correct subspecialty neurologist and prerequisite diagnostic tests. AAD was successfully implemented in the neurology clinic, with rapid turn around and increased utilization and accuracy over this pilot period.Disclosure: Dr. Malik has nothing to disclose. Dr. Barron has nothing to disclose. Dr. Holland has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Malik, M. T., Barron, K., Holland, N. Tags: Practice, Policy, and Ethics Source Type: research

Exploring the Role of the Hippocampus in Migraine (S47.008)
Conclusions:Migraine patients have less hippocampal volume compared to healthy controls. Migraineurs with less hippocampal volume have more severe symptoms of allodynia suggesting involvement of the hippocampus in migraine-related cutaneous allodynia.Study Supported by: NIH K23NS010891Disclosure: Dr. Chong has nothing to disclose. Dr. Dumkrieger has nothing to disclose. Dr. Schwedt has received personal compensation for activities with Allergan, Amgen, Autonomic Technologies Inc, Avanir, Dr. Reddy's, GBS, Second Opinion, Supernus, and Teva as a consultant and advisory board member. Dr. Schwedt has received personal compens...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chong, C., Dumkrieger, G., Schwedt, T. Tags: Headache: Basic and Clinical Science Source Type: research

Epidemiology of Migraine in Men: Disease Presentation and Comorbidities from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study (S47.007)
Objective:To evaluate the difference in the epidemiology of migraine in men compared with women.Background:This analysis from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study highlights migraine epidemiology in men by examining sex differences in migraine disease presentation and comorbidities.Design/Methods:CaMEO participants were recruited from an online panel using quota sampling and completed baseline and 3-month follow-up surveys. Sociodemographic and headache features, headache-related disability (Migraine Disability Assessment [MIDAS]), symptom severity (Migraine Symptom Severity Score [MSSS]), cutaneous...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Scher, A., Wang, S.-J., Katsarava, Z., Buse, D., Fanning, K., Adams, A. M., Lipton, R. Tags: Headache: Basic and Clinical Science Source Type: research

Migraine is comorbid with Attention Deficit Hyperactivity Disorder in childhood: a nationwide populational study (S47.006)
Conclusions:The results suggest that any migraine subtype and ADHD are comorbid in childhood. Providers and educators should be aware of the association. By identifying children with ADHD and comorbid migraine, practitioners will be more capable to offer a complete and holistical therapeutic approach, maximizing the chance for improvement and the outcomes of therapy.Disclosure: Dr. Arruda has nothing to disclose. Dr. Arruda has nothing to disclose. Dr. Guidetti has nothing to disclose. Dr. Bigal holds stock and/or stock option in Teva which sponsored research in which Dr. Bigal was involved as an investigator. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Arruda, M., Arruda, R., Guidetti, V., Bigal, M. Tags: Headache: Basic and Clinical Science Source Type: research

Green light alleviates migraine photophobia (S47.005)
Conclusions:The study reveals a mechanism for the finding that exposure to green light exacerbates migraine headache significantly less than exposure to white, blue, amber or red lights in patients with normal eyesight. Taking into consideration results of ERG, thalamic and VEP recordings, the findings suggest that migraine photophobia may originate in the retina and fine-tuned in the thalamus, rather than in the cortex – a major shift in current thinking. Mechanistically, the psychophysical findings are explained by the differential responses of cone-driven retinal pathways, light-sensitive thalamic neurons in 2 sen...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Noseda, R., Reuven-Nir, R., Bernstein, C., Borsook, D., Buettner, C., Burstein, R. Tags: Headache: Basic and Clinical Science Source Type: research

Increased cortical network activity in a migraine mutant mouse following traumatic brain injury (S47.004)
Conclusions:Our data suggest that CK1d mutant animals show a distinct response to TBI, consistent with an increase in network excitability, and congruent with the increased susceptibility to PTH seen in migraineurs.Study Supported by: NIH R01 NS085413, DoD CDMRP PR130373Disclosure: Dr. Service has nothing to disclose. Dr. Sawant-Pokam has nothing to disclose. Dr. Mendez has nothing to disclose. Dr. Brennan has received personal compensation for activities with MAP Pharmaceuticals and Allergan as a member of an advisory board. Dr. Brennan received research support from Electrocore LLC. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Service, C. A., Sawant-Pokam, P., Mendez, J., Brennan, K. C. Tags: Headache: Basic and Clinical Science Source Type: research

In vivo imaging of CSD-induced activation of resident meningeal immune cells: implications for activation of meningeal nociceptors (S47.003)
Conclusions:The findings raise the possibility that activation of immune cells in the pia and dura after CSD may be involved in the activation of meningeal nociceptors, potentially by rendering the environment in which nociceptors reside more inflamed – a condition shown previously as sufficient for activation of nociceptors.Study Supported by: NIH/NINDS grants R37 NS079678, RO1 NS069847, R21 NS085510Disclosure: Dr. Schain has nothing to disclose. Dr. Melo-Carrillo has nothing to disclose. Dr. Strassman has nothing to disclose. Dr. Burstein has received personal compensation for activities with Allergan, GSK, and Mer...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Schain, A., Melo-Carrillo, A., Strassman, A., Burstein, R. Tags: Headache: Basic and Clinical Science Source Type: research

Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: implications to extracranial origin of headache (S47.002)
Conclusions:Because the up-regulated genes were linked to activation of white blood cells, production of cytokines, and inhibition of NFKB, and the down-regulated genes linked to prevention of macrophage activation and cell lysis, the findings suggest that the molecular environment surrounding periosteal pain fibers is inflamed. If confirmed in larger and independent studies, the findings can establish a basis for activation of trigeminovascular nociceptors that reach the affected periosteum through suture branches of intracranial meningeal nociceptors and/or somatic branches of the occipital nerve. This study provides the...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Burstein, R., Blake, P., Perry, C. Tags: Headache: Basic and Clinical Science Source Type: research

Cortical spreading depression closes the paravascular space and impairs glymphatic flow: Implications for migraine headache. (S47.001)
Conclusions:Our findings demonstrate a link between migraine and the glymphatic system, and suggest a novel mechanism for regulation of glymphatic flow. Because CSD is involved in the production of many potentially harmful interstitial molecules, the blockade of their route of clearance could facilitate cortical changes, gliosis, and the headache.Study Supported by: NIH/NINDS grants R37 NS079678, RO1 NS069847Disclosure: Dr. Schain has nothing to disclose. Dr. Strassman has nothing to disclose. Dr. Melo-Carrillo has nothing to disclose. Dr. Burstein has received personal compensation for activities with Allergan, GSK, and M...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Schain, A., Strassman, A., Melo-Carrillo, A., Burstein, R. Tags: Headache: Basic and Clinical Science Source Type: research

PREPL deficiency: delineation of the phenotype and development of a functional blood assay (S46.008)
Conclusions:This novel blood test facilitates the diagnosis and confirmation of PREPL deficiency. Together with the emerging knowledge about the particular clinical course and the possible treatments for PREPL deficiency, this should enable better clinical care for these patients.Study Supported by:FWO Vlaanderen (Luc Régal and John Creemers)European Community 7th FP grant 223077 (John Creemers)Marie-Marguerite Delacroix Fund (Luc Régal)Prader-Willi research foundation (Luc Régal and John Creemers)Disclosure: Dr. Regal has received personal compensation for activities with Genzyme and Shire. Dr. Marten...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Regal, L., Martensson, E., Maystadt, I., Voermans, N., Lederer, D., Burlina, A., Fita, M. J. J., Hoogeboom, A. J. M., Engman, M. O., Hollemans, T., Schouten, M., Meulemans, S., Jonson, T., Francois, I., Ortega, D. G., Kamsteeg, E.-J., Creemers, J. Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research

Physician- and Patient-Reported Outcomes in {chi}-linked Adrenoleukodystrophy: Accelerated Roadmap from Patients Insights to Clinical Trials (S46.007)
Conclusions:The aggregation of physician- and patient-reported outcomes in ALD/AMN presents a tremendous opportunity to better understand what matters to patients and to leverage their insights in combination with natural history data for clinical trial design optimization and moving the disease into clinical trial readiness state.Study Supported by:ALD Connect and ALD/AMN patients and their familiesDisclosure: Dr. Sherman has nothing to disclose. Dr. Connors has nothing to disclose. Dr. Walsh has nothing to disclose. Dr. Eichler has received research support from Bluebird Bio and Vertex Pharmaceuticals. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Sherman, A., Connors, E., Walsh, K., Eichler, F. Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research

Long term outcomes and risk factors for chemotherapy induced peripheral neuropathy in childhood cancer survivors (s46.006)
This study aimed to evaluate the prevalence, impact and risk factors for chemotherapy induced peripheral neuropathy (CIPN) in long term childhood cancer survivors (CCS).Background:Neurotoxic chemotherapy is frequently used for the treatment of childhood cancer and CIPN may be an important cause of morbidity in CCS, contributing to reduced physical function and restricted participation in day-to-day activities.Design/Methods:Comprehensive neurotoxicity assessments were undertaken in CCS who completed platinum or vinca alkaloid based chemotherapy>5 years ago, comprising of clinical, functional, quality of life and neuroph...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kandula, T., Farrar, M., Kiernan, M., Mizrahi, D., Carey, K., Krishnan, A., Cohn, R., Park, S. Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research

A Randomized Double-blind, Placebo-controlled, Cross-over Trial of Ganaxolone in Children and Adolescents with Fragile X Syndrome (S46.005)
Conclusions:Ganaxolone was generally safe and well tolerated in children with FXS and showed improvements in anxiety, hyperactivity and attention in a subset of patients with baseline anxiety.Study Supported by:U.S. Army Medical Research and Material Command (USAMRMC) FUNDING MECHANISM: Contract # W81XWH-11-1-0626Jérôme Lejeune foundation, Marguerite Marie Delacroix foundation, FRAXA Research FoundationDisclosure: Dr. Tsai has received personal compensation for activities with Marinus. Dr. Tsai has received research support from Marinus. Dr. Ligsay has nothing to disclose. Dr. Van Dijck has nothing to disclose...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Tsai, J., Ligsay, A., Van Dijck, A., Kooy, F., Hessl, D., Bickel, E., Hagerman, R., Patroneva, A. Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research

Motor mapping by transcranial magnetic stimulation reveals a pathologically preserved immature motor lateralization in patients with intractable focal epilepsy (S46.004)
Objective:To test whether immature uncrossed corticospinal projections are maintained in the epileptogenic hemisphere in focal cortical childhood epilepsy.Background:While corticospinal connections are bilateral at birth, a predominantly contralateral corticospinal pattern develops by the toddler years. Early life acquired unilateral injury can alter the normal development of laterality such that uncrossed corticospinal connections persist in the uninjured hemisphere. Here, we evaluate whether focal epilepsy is also associated with abnormal patterns of laterality in the motor system.Design/Methods:Children with intractable...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kaye, H., Gersner, R., Boes, A., Pascual-Leone, A., Rotenberg, A. Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research

Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy (S46.003)
Conclusions:The NURTURE interim analysis shows that all the infants treated with nusinersen are alive and generally achieving new motor skills and appropriate age-related developmental gains. The efficacy and safety profile of nusinersen supports continued clinical development.Study Supported by: BiogenDisclosure: Dr. De Vivo has received personal compensation for activities with AveXis, Biogen, Roche, IONIS, Sarepta, Cytokinetics Pharmaceuticals, and the SMA Foundation. Dr. De Vivo has received research support from NIH, DOD, SMA Foundation,and Hope for Children Research Foundation. Dr. Hwu has nothing to disclose. Dr. Re...
Source: Neurology - April 17, 2017 Category: Neurology Authors: De Vivo, D. C., Hwu, W.-L., Reyna, S. P., Farwell, W., Gheuens, S., Sun, P., Zhong, Z. J., Su, J., Schneider, E., Bertini, E., on behalf of the NURTURE Study Investigators Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research

Outcome following hemicraniectomy in children with acute stroke in the International Pediatric Stroke Study (S46.002)
Conclusions:Hemicraniectomy in pediatric stroke is preformed infrequently. Death does occur in these children at a low rate of 5%. The majority of children had moderate to severe deficits. Overall children who have hemicraniectomies continue to have significant neurologic deficits following the procedure. Prospective studies are needed to examine long term morbidity following hemicraniectomy.Disclosure: Dr. Lehman has nothing to disclose. Dr. Dowling has received personal compensation for activities with Neurology Review and Educational Testing Consultants, Inc. Dr. Felling has nothing to disclose. Dr. Chung has nothing to...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Lehman, L., Dowling, M., Felling, R., Chung, M., Pergami, P., Guilliams, K., DeVeber, G., Rivkin, M. Tags: Child Neurology: Molecular Biology to Clinical Trials Source Type: research